Prostate cancer does not have ten stages. The formal staging system runs from stage I through stage IV, and the confusion almost certainly comes from two other numbering systems that patients encounter alongside their stage: the Gleason score, which historically ranged from 2 to 10, and the CAPRA risk score, which runs from 0 to 10. All three numbers describe different things about the same cancer, and understanding which is which matters a lot for making sense of a diagnosis.
Why the Numbers Get Confusing
When you are diagnosed with prostate cancer, you will typically hear several numbers thrown at you in quick succession. The stage (I through IV) describes how far the cancer has spread. The Gleason score (now expressed as a Grade Group from 1 to 5) describes how aggressive the cancer cells look under a microscope. And your doctor may also mention a risk score like CAPRA, which combines five different clinical measurements into a single number from 0 to 10. Each of these numbers captures something different, and none of them alone tells the full story. A man with a low stage can still have an aggressive-looking cancer, and a man with a high Gleason score can still have disease that has not spread beyond the prostate.
The Actual Staging System
Prostate cancer staging uses the TNM system, which stands for Tumor, Nodes, and Metastasis. The T category describes whether the tumor is confined to the prostate (T1 and T2) or has grown into surrounding tissues (T3 and T4). N indicates whether nearby lymph nodes contain cancer. M tells you whether cancer has spread to distant organs, most commonly bone. These three letters combine into an overall stage from I to IV, with stage I meaning the cancer is small, low-grade, and confined to the prostate, and stage IV meaning it has spread to distant sites.
Within each stage there are substages. Stage II, for example, is divided into IIA, IIB, and IIC based on tumor size and grade. Stage III splits into IIIA through IIIC, with IIIC reserved for cancers that have grown into neighboring structures like the bladder or rectum but have not yet reached lymph nodes or distant organs. Stage IV covers both lymph-node-positive disease (IVA) and distant metastases (IVB). So while the broad system has four stages, the substages give doctors a more granular picture.
The Gleason Score and Grade Groups
The Gleason scoring system is where the “1 to 10” idea likely comes from. Developed over 50 years ago, it originally assigned two pattern scores from 1 to 5 based on how abnormal the cancer tissue looked, then added them together for a combined score of 2 to 10. In practice, scores below 6 are almost never assigned anymore. The system has been revised repeatedly to improve its ability to predict outcomes and to reduce disagreement between pathologists reading the same biopsy slides.
The most important recent change was the introduction of Grade Groups, which collapse the old Gleason scores into five tiers. Grade Group 1 corresponds to Gleason 6 (or less), Grade Group 2 to Gleason 3+4=7, Grade Group 3 to Gleason 4+3=7, Grade Group 4 to Gleason 8, and Grade Group 5 to Gleason 9 or 10. This shift happened because telling a patient they have “Gleason 6 out of 10” made it sound like they were already more than halfway to the worst possible cancer, when in reality Gleason 6 is the lowest grade typically assigned and has an excellent prognosis. Grade Group 1 out of 5 communicates that more honestly.
The distinction between certain Gleason patterns remains challenging even for experts. Telling apart some grade 4 tissue patterns from grade 3 is difficult, and that boundary matters because it separates patients who could potentially defer treatment from those who need it sooner. Research has found that specific architectural patterns within grade 4, particularly a pattern called cribriform, carry worse outcomes than other grade 4 subtypes, which has prompted calls for even finer subdivisions within the grading system.1Wiley Online Library / Histopathology. Grading of prostate cancer: a work in progress
The CAPRA Score and the Real 0 to 10 Scale
If someone told you prostate cancer is scored from 0 to 10, they were probably describing the CAPRA score. Developed at the University of California, San Francisco, this tool combines five clinical measurements: PSA level (the blood test), Gleason score, T stage, the percentage of biopsy cores that contain cancer, and the patient’s age. Each factor contributes points, and the total ranges from 0 to 10.2PubMed Central. The UCSF Cancer of the Prostate Risk Assessment (CAPRA) Score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy
The score is designed to predict how likely the cancer is to come back after treatment. Roughly speaking, the risk of recurrence doubles for every two-point increase in the score. In the original study, men with a CAPRA score of 0 or 1 had about an 85 percent chance of remaining free of recurrence at five years, while men scoring 7 to 10 had only about an 8 percent chance.3PubMed Central. The UCSF Cancer of the Prostate Risk Assessment (CAPRA) Score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy The score has been validated internationally, including in populations outside the United States.4Japanese Journal of Clinical Oncology. External Validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese Patients Receiving Radical Prostatectomy
CAPRA is not the only risk stratification tool. Most doctors also use a simpler three-tier system (low, intermediate, and high risk) developed by Anthony D’Amico, which groups patients based on their PSA, Gleason score, and clinical stage. But CAPRA’s 0-to-10 scale offers finer resolution, and it is the number system that most closely matches what someone searching for “prostate cancer stages 1 to 10” is probably encountering.
Low-Risk Disease and Active Surveillance
For men with low-risk prostate cancer — typically stage I or II, Grade Group 1, and a low PSA — active surveillance has become the standard recommendation rather than immediate surgery or radiation. This approach involves regular monitoring with blood tests, imaging, and periodic biopsies, with treatment triggered only if the cancer shows signs of becoming more aggressive.
The safety record for this strategy is strong. A large prospective study found that the cumulative rate of dying from prostate cancer or developing metastases among men on active surveillance for Grade Group 1 disease was about 0.1 percent at both 10 and 15 years.5PubMed. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort Broader reviews of active surveillance programs have reported cancer-specific mortality in the range of 0.5 to 3 percent over 10 to 15 years, with the higher numbers reflecting programs that also enroll some men with slightly higher-risk features.6PubMed. Active surveillance for low-risk prostate cancer The key is that about a third of men on surveillance will eventually be reclassified as higher risk on a repeat biopsy and offered treatment at that point, while the rest avoid the side effects of surgery or radiation entirely.
Intermediate-Risk Disease
Intermediate-risk prostate cancer is where treatment decisions get genuinely complicated. These are men with Gleason 7 (Grade Group 2 or 3), a moderately elevated PSA, or a clinical stage of T2b or T2c. The main treatment options are surgery, external beam radiation, and brachytherapy (radioactive seed implants), and all three produce broadly similar long-term survival.7PubMed. Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy?
Where the treatments differ is in their side effects and in their biochemical failure rates, which refers to how often PSA rises again after treatment (suggesting the cancer may be returning). One study of over 1,500 men found that brachytherapy had a ten-year freedom from biochemical failure of about 80 percent, compared to roughly 57 percent for both surgery and external radiation. But when the researchers looked at metastasis-free survival and prostate cancer–specific survival, the three treatments were not significantly different after adjusting for age and health status.8PubMed. Ten-Year Treatment Outcomes of Radical Prostatectomy Vs External Beam Radiation Therapy Vs Brachytherapy for 1503 Patients With Intermediate-risk Prostate Cancer A larger database study found that surgery was associated with lower adjusted mortality risk compared to external radiation, though database studies like this have inherent limitations because healthier men tend to be offered surgery in the first place.9Clinical Genitourinary Cancer. Survival Outcomes of Radical Prostatectomy Versus Radiotherapy in Intermediate-Risk Prostate Cancer: A NCDB Study
The practical upshot for intermediate-risk patients is that the “best” treatment depends heavily on your age, health, priorities around sexual function versus urinary function, and whether your Grade Group is 2 or 3 (since 3 behaves more aggressively than 2 despite both being called “Gleason 7”).
High-Risk and Locally Advanced Disease
High-risk prostate cancer — generally Gleason 8 or above, very high PSA, or stage T3/T4 — is treated more aggressively. The combination of radiation therapy with long-term hormone therapy (androgen deprivation therapy, or ADT) has become a standard approach.10PubMed. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial A systematic review and meta-analysis found that adding radiation to hormone therapy significantly improved overall survival, progression-free survival, and reduced prostate cancer–specific death compared to hormone therapy alone, with especially strong benefits in men with locally advanced or lymph-node-positive disease.11PubMed Central. Efficacy of androgen deprivation therapy (ADT) in combination with radiation therapy, compared to ADT alone in patients with high-risk prostate cancer: an updated systematic review and meta-analysis
Surgery remains an option for some high-risk patients, and a systematic review of first-line treatments concluded that surgery or radiation combined with hormone therapy produced the best survival outcomes, while watchful waiting had the worst.12Scientific Reports. Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer The choice between surgery and radiation in this group depends on the specifics of how far the tumor extends and whether it can be safely removed.
Metastatic Prostate Cancer
Stage IV prostate cancer that has spread to bone or other organs is treated primarily with systemic therapies. The backbone is hormone therapy, but adding chemotherapy (docetaxel) to hormone therapy at the start of treatment extended median overall survival from about 44 months to nearly 58 months in a landmark trial.13PubMed Central. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
More recently, “triplet therapy” — combining hormone therapy, chemotherapy, and a newer class of drugs that block androgen receptor signaling — has shown even better results. A meta-analysis of five randomized trials found that triplet therapy improved overall survival compared to the combination of hormone therapy and docetaxel alone, particularly in men with newly diagnosed metastatic disease.14PubMed. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis Treatment for advanced prostate cancer has changed more in the past decade than in the prior thirty years, with several new drugs entering practice.
When metastatic disease stops responding to hormone therapy — a state called castration-resistant prostate cancer — targeted radionuclide therapy has emerged as an option. A trial of lutetium-177-PSMA-617, a radioactive drug that seeks out prostate cancer cells by targeting a protein on their surface, found that it extended median overall survival from about 11 months to about 15 months and more than doubled the time before the cancer progressed on imaging.15PubMed Central. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
The Biopsy Grade Does Not Always Match the Surgical Grade
One source of real anxiety for patients is that the Gleason score assigned from a biopsy does not always match what the pathologist finds when the whole prostate is removed surgically. In a large British registry study, the biopsy grade and the surgical grade matched only about 59 percent of the time. About a quarter of men were upgraded (the surgical specimen was more aggressive than the biopsy suggested), and roughly 16 percent were downgraded. Upgrading was most common among men initially classified as low risk, with over half of those men receiving a higher grade after surgery.16PubMed Central. Pathological upgrading in prostate cancer treated with surgery in the United Kingdom: trends and risk factors from the British Association of Urological Surgeons Radical Prostatectomy Registry Other research has estimated that upgrading from biopsy to surgical specimen occurs in up to a third of patients treated with surgery.17Exploration of Targeted Anti-tumor Therapy. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy
This mismatch is a fundamental limitation of biopsy-based grading: the needle samples only a small fraction of the prostate, and the most aggressive area might be missed. It is one of the reasons doctors combine the Gleason score with PSA, imaging, and sometimes genomic tests rather than relying on any single number.
How Imaging Shapes Staging Accuracy
The accuracy of staging depends heavily on what imaging you get. Traditional staging with CT scans and bone scans is being supplemented or replaced by PSMA PET/CT, a newer scan that detects a protein (PSMA) found on the surface of most prostate cancer cells. PSMA PET/CT has improved the detection of both local and distant disease.18PubMed Central. PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer
One of the most striking findings in recent years is that conventional bone scans overstage disease at initial diagnosis. An international study with blinded readers found that at initial staging, 57 percent of bone scans that were read as positive for metastases were actually false positives when compared against PSMA PET as the reference standard.19Journal of Nuclear Medicine. Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers That means a substantial number of men who were told their cancer had spread to bone based on an older-style scan may have actually had localized disease that could have been treated more aggressively. As PSMA PET becomes more widely available, staging accuracy should improve, though the scans are still not universally accessible.
MRI also plays a role, particularly multiparametric MRI for evaluating whether cancer has grown beyond the prostate capsule. A multicenter study found that MRI had a sensitivity of only 38 percent for detecting spread outside the prostate, though this improved to 62 percent with a newer standardized reporting system.20PubMed. Evaluation of the accuracy of multiparametric MRI for predicting prostate cancer pathology and tumour staging in the real world: an multicentre study MRI is better at ruling in extraprostatic disease (when it says cancer has spread, it is right about 90 percent of the time) than ruling it out.
Genomic Tests Add a Layer Beyond Stage and Grade
Traditional staging tools — PSA, Gleason score, T stage — do not fully capture how an individual cancer will behave. Two men with identical clinical profiles can have very different outcomes. This is where genomic classifiers like Decipher have gained traction. Decipher analyzes the expression of 22 genes in a tumor specimen and produces a score that helps refine risk beyond what the standard clinical tools can provide.21PubMed Central. The Clinical Impact of the Decipher Genomic Classifier in Prostate Cancer
Recent work combining Decipher scores with clinical staging systems has shown dramatic reclassification effects. When genomic data was integrated with clinical risk factors, estimates of 10-year prostate cancer death ranged widely, from about 0.1 percent to nearly 49 percent. In one analysis, integrating genomic information led to significant reclassification of patients, with roughly 23 percent upstaged and 46 percent downstaged by at least one stage compared to clinical staging alone.22Prostate Cancer and Prostatic Diseases. Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer Combining Decipher scores with tools like the CAPRA postsurgical score also improved prognostic accuracy beyond what either measure offered on its own.23European Urology Oncology. Prognostic Implications of Very High Decipher Scores in Prostate Cancer: Towards a Refined Genomic Risk Classification
Oligometastatic Disease and the Blurring of Stage Boundaries
One of the more interesting developments in prostate cancer staging is the recognition of “oligometastatic” disease — a state where a man has a small number of metastases (typically one to three) rather than widespread spread. This concept treats metastatic disease not as a single category but as a spectrum, with a small number of metastases potentially representing a disease state that can still be controlled with targeted treatment.24PubMed Central. Oligometastatic Prostate Cancer: Current Status and Future Challenges
Better imaging, particularly PSMA PET, has made it easier to identify these patients. Early clinical trials treating individual metastases with focused radiation or surgery have provided evidence that this approach can delay the need for systemic therapies like hormone treatment.25PubMed Central. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations The concept is still evolving, and there is no universally agreed-upon definition of how many metastases qualify as “oligo.” But it represents a meaningful shift in thinking: stage IV is no longer treated as a monolithic category where everyone gets the same systemic approach.
When PSMA PET is used to detect biochemical recurrence after initial radiation therapy, roughly 72 percent of scans detect disease. Among those positive scans, about 81 percent show oligometastatic disease, and only 19 percent show widespread metastases.26PubMed. PSMA PET/CT for the detection of prostate cancer biochemical recurrence after primary radiation therapy: is it time to review the Phoenix criteria? Many of these men might previously have been assumed to have widespread disease and treated accordingly, when in fact targeted therapy for a few sites might be a reasonable option.
Racial Disparities in Diagnosis Stage
Staging is not only a biological question — it is also influenced by when and how men access the healthcare system. Black men in the United States are diagnosed with later-stage prostate cancer at higher rates than white men, and this disparity persists even in affluent communities. One study found that Black race roughly doubled the odds of being diagnosed at a later stage, and Black men were also more likely to be diagnosed at a younger age.27PubMed Central. Racial Disparities in Prostate Cancer Stage at Diagnosis Persist Despite Community Affluence Current smoking was also a significant contributor to later-stage diagnosis. These findings suggest that the stage at which prostate cancer is caught is not purely a function of tumor biology but is also shaped by patterns in screening access, healthcare utilization, and potentially biological differences in cancer aggressiveness.
Artificial Intelligence in Grading
Given the subjectivity involved in Gleason grading, there is growing interest in using artificial intelligence to assist pathologists. The largest histopathology competition to date, called PANDA, involved over 1,200 algorithm developers analyzing more than 10,000 digitized prostate biopsies. The best-performing algorithms achieved agreement with expert pathologists at a level comparable to the agreement between pathologists themselves, and this held up across patient populations from different continents and different laboratories.28Nature Medicine. Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge Reviews of the field have concluded that while AI can match experienced uropathologists in grading accuracy, more work is needed before these tools can be reliably deployed across the full diversity of clinical settings.29PubMed. Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer in Biopsies-Current Status and Next Steps If AI grading does become routine, it could reduce the variability that currently contributes to the biopsy-versus-surgery grading mismatch, potentially giving patients more reliable risk information earlier.